• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Bye-Bye China?

    Decentralized Trials Fuel AI Revolution in Clinical Research

    Self-Medication: Flexibility for Patients and Drug Manufacturers

    The Single-Use Mixing Landscape: Evaluating Your Options

    DCAT President Talks COVID-19, Drug Manufacturing and Innovation
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Aphena’s $21M Cookeville Expansion Nears Completion

    BioMed X Partners with Jansen Research & Development LLC

    Care Access Research, AstraZeneca Partner on COVID-19 Antibody Trial

    500+ Sites Join Inato’s Industry Marketplace

    Caprion-HistoGeneX Rebrands as CellCarta
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Aphena’s $21M Cookeville Expansion Nears Completion

    PromoCell Receives EXCiPACT Certification

    Civica to Build an Essential Medicines Manufacturing Facility in Virginia

    Humanigen, Emergent Enter Covid-19 Partnership

    Samsung Bioepis Opens New Headquarters
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Aphena’s $21M Cookeville Expansion Nears Completion

    Civica to Build an Essential Medicines Manufacturing Facility in Virginia

    WDSrx Expands Warehouse Network

    Catalent Acquires Acorda’s INBRIJA Manufacturing Operations

    Varcode, PL Developments Form Strategic ‘Smart Tag’ Pact
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Care Access Research, AstraZeneca Partner on COVID-19 Antibody Trial

    Caprion-HistoGeneX Rebrands as CellCarta

    Humanigen, Emergent Enter Covid-19 Partnership

    Samsung Bioepis Opens New Headquarters

    Lilly Completes $1B Acquisition of Prevail
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Top BioPharma Form Accumulus Synergy

    Global Biosciences Co. Selects ValGenesis VLMS

    Gene Therapy Co. Selects ValGenesis' SaaS Platform

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Samsung Biologics Adopts Veeva Vault QMS to Unify Quality Management
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Alcami

    Syngene

    Reed-Lane

    Cytovance Biologics

    Almac Group
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Reed-Lane

    Adare Pharma Solutions

    Aphena Pharma Solutions

    Emergent BioSolutions

    PCI Pharma Services
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Expert's Opinion

    Navigating Uncertainty: Considerations for Life Sciences 2021

    With vaccines against COVID-19 on the horizon, our focus is shifting to 2021 and the major issues life sciences companies face and reasons for optimism.

    Navigating Uncertainty: Considerations for Life Sciences 2021
    Related CONTENT
    • Civica to Build an Essential Medicines Manufacturing Facility in Virginia
    • Virtual Clinical Trials: The Future of Dermatology Studies
    • Fujifilm Diosynth Biotechnologies Begins COVID-19 Vax Production
    • The Alcami Advantage
    • The Changing R&D Landscape
    Arda Ural , EY Americas Health Sciences and Wellness Industry Leader, Ernst & Young LLP12.11.20
    Throughout this year, uncertainty has been the prevailing theme for investors and executives trying to make informed capital allocation decisions. The unpredictable course of the pandemic, alongside economic turbulence and the rapid development of vaccines and therapeutics, has particularly challenged health care systems and life sciences companies.

    At this moment in Q4 2020, it appears that we are at an inflection point, with many variables in play over the months to come. Simply put, short-term uncertainty is expected to last until Spring until two to three approved vaccines are successfully distributed and administered to help the population attain threshold herd immunity at 60%.

    Although there are critical areas that life sciences executives must observe at this inflection point, I believe these considerations are tempered by encouraging news as well.

    Continued COVID-19 headwinds
    During the initial surge of the pandemic, we witnessed the significant downstream impact health care systems acutely focused on to address the needs of COVID-19 patients. Consider this study from nine high-volume US cardiac catheterization laboratories, which found a 38% decrease in patients treated for ST-elevation myocardial infarction, a life-threatening condition. Beyond these human tolls, the ripple effects of further delayed medical procedures and screenings will continue to be felt by health care providers and pharmaceutical companies alike.

    The need for consistency and unity between pharmaceutical companies, regulators and policymakers has never been greater. With 48 vaccines for COVID-19 currently at some stage of clinical trials, it’s been an all-out innovation sprint to develop a safe and protective vaccine. But with surveys showing vaccine hesitancy with only 58% of the population willing for inoculation, industry leaders must collaborate with government to prioritize public health for the long term.

    The pandemic has illuminated the need for resiliency by re-onshoring manufacturing of essential medicines so there are no interruptions to supply chain. Now is the time to reimagine the future of the pharmaceutical supply chain, not only for producing the therapeutics needed to treat COVID-19 and replenishing the Strategic National Stockpile but also for long-term planning to build a resilient supply chain network to pre-empt future disruptions caused by natural disasters, geopolitical risk or pandemics alike.

    Tailwinds on the horizon
    Across the life sciences sector, there’s reason for executives to be optimistic in the year ahead. Liquidity and balance sheets are strong, with $1.45t in dry powder for pharma alone. Although M&A and other deal making slowed earlier this year, there’s reason to believe that activity will continue apace, fueling further business growth through targeted bolt-on acquisitions and financing innovative technologies and platforms at biotechs.

    COVID-19 in particular has demonstrated the incredible capacity and speed of innovation of the biopharma industry. Consider this: although the first Ebola outbreak was reported in 1976, a vaccine was only approved by the U.S. FDA in 2019. There are no approved vaccines for two other coronaviruses, SARS and MERS, which were first reported in 2003 and 2012, respectively. With 48 new molecular entities accepted and approved by the FDA as of early December, the year-over-year analysis of innovations suggests a strong pipeline in place to replenish the sector’s aging portfolio.

    More broadly across the life sciences spectrum, it is a strong time for IPOs, including follow-ons and the comeback of special purpose acquisition companies (SPACs). As of July, there were 100 SPACs seeking acquisitions, with over $30b in equity held in trust. With a strong flow of capital, low interest rates and strong performance by biotech stocks, it’s likely that we’ll see continued activity in this space, especially across the health care and life sciences sectors.

    Turning to political influences on industry, there’s good reason for executives to feel positive following what was a contentious election cycle. Analysis shows that over the last thirty years, the S&P 500 Health Care Index, which includes pharma companies, medical device makers, biotechs and payors, has shown an 18% annual return during a Democratic presidency, compared with a 4% return during Republican administrations.

    In fact, during a Democratic presidency with a split Congress, as may be the result of the runoff Senate elections in Georgia, the average returns were 22%. Although past is not prologue, these insights should give life science executives a high degree of confidence to move ahead with capital deployment on digital capabilities, supply chain resiliency and M&A – especially divesting non-core assets at historically favorable valuations.

    While there appears to be a clearer path toward a new normalcy, I encourage life sciences companies to stay resilient and agile by keeping these headwinds and tailwinds top of mind. Perhaps the only thing that is certain is uncertainty — a fitting thought as we close out this unpredictable year.
     


    Arda Ural is EY’s Americas Industry Markets Leader for Life Sciences and Healthcare. Arda started his career almost 30 years ago with a leading global pharmaceutical company where he held brand leadership and new product development roles. Subsequently, he led the commercial organization of a Biotech company and held Strategy and BU leadership roles at a global Medical technology company. Prior to joining EY, he was a Managing Director at a strategy consulting firm for six years, where he led the Life Sciences M&A Practice.
    Related Searches
    • Drug Development
    Suggested For You
    Civica to Build an Essential Medicines Manufacturing Facility in Virginia Civica to Build an Essential Medicines Manufacturing Facility in Virginia
    Virtual Clinical Trials: The Future of Dermatology Studies Virtual Clinical Trials: The Future of Dermatology Studies
    Fujifilm Diosynth Biotechnologies Begins COVID-19 Vax Production Fujifilm Diosynth Biotechnologies Begins COVID-19 Vax Production
    The Alcami Advantage The Alcami Advantage
    The Changing R&D Landscape The Changing R&D Landscape
    Aurigene Pharmaceutical Services ltd. Aurigene Pharmaceutical Services ltd.
    Structural Characterization of Biologics Using High-Resolution Mass Spectrometry Structural Characterization of Biologics Using High-Resolution Mass Spectrometry
    Food Studies Food Studies
    RTP Laboratory RTP Laboratory
    RTP Formulation & Sterile Fill-Finish Facility RTP Formulation & Sterile Fill-Finish Facility
    Samsung Biologics Adopts Veeva Vault QMS to Unify Quality Management Samsung Biologics Adopts Veeva Vault QMS to Unify Quality Management
    Advancing Digital Endpoints in Clinical Trials Advancing Digital Endpoints in Clinical Trials
    Logistics4Pharma Facility Passes Inspection Logistics4Pharma Facility Passes Inspection
    atbtherapeutics, iBio CDMO Enter Manufacturing Agreement atbtherapeutics, iBio CDMO Enter Manufacturing Agreement
    Initium Therapeutics Launches Antibody Development Platform Initium Therapeutics Launches Antibody Development Platform

    Related Expert's Opinion

    • Clinical Trials | Drug Development | Information Technology
      Virtual Clinical Trials: The Future of Dermatology Studies

      Virtual Clinical Trials: The Future of Dermatology Studies

      COVID-19 has created lasting impacts for clinical trials and a host of benefits have arisen from the adoption of virtual and hybrid models.
      Sonja VanWye, RN, MSN, Director, Dermatology Strategy, IQVIA Biotech 01.15.21

    • Clinical Trials | Drug Development
      The Slow – But Desperately Needed – Evolution of Oncology Clinical Development Designs

      The Slow – But Desperately Needed – Evolution of Oncology Clinical Development Designs

      Appropriate adaptive designs in early stages of development can accelerate timelines and reduce costs, and help focus on the most promising agents.
      Jürgen Hummel, MSc, Senior Director, Statistical Science, PPD, and Lead of PPD’s Adaptive Design Working Group 01.07.21

    • Drug Development | Industry News | Regulatory Affairs
      The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

      The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

      A look at EUA standards and approvals, unavoidable pitfalls, Operation Warp Speed, FDA’s use of Real-World Evidence, and a slow return to "normalcy".
      Chad Landmon, Michelle Divelbiss and Alex Alfano, Axinn, Veltrop & Harkrider LLP's Intellectual Property and Food and Drug Administration Practice Groups 01.05.21


    • Clinical Trials | Drug Development | Information Technology
      Advances in Intelligent Automation

      Advances in Intelligent Automation

      The future of medicine relies on further digital transformation and automation-enabling solutions to improve drug development and monitoring.
      Updesh Dosanjh, Practice Leader, Technology Solutions, IQVIA 12.14.20

    • Drug Development
      New York City is Not Dead, Our Life Sciences Sector is Thriving

      New York City is Not Dead, Our Life Sciences Sector is Thriving

      Amid the COVID-19 pandemic, life sciences is booming in NYC!
      Sara Jane Demy, CEO & Founder, Demy-Colton 10.01.20

    • Clinical Trials | Drug Development
      How to Balance Internal and External Staff Within Outsourcing Models

      How to Balance Internal and External Staff Within Outsourcing Models

      Strategies to consider in flexed staffing models.
      John Barry, SVP, Consulting Practice and Chief Strategy Officer, PRA Health Sciences, SSD 09.22.20


    • Biologics, Proteins, Vaccines | Drug Development
      The Importance of Global Collaboration in the Fight Against COVID-19

      The Importance of Global Collaboration in the Fight Against COVID-19

      Industry continues to join forces to find new treatments for COVID-19.
      Dohyun Cho, Chief Operating Officer, Enzychem Lifesciences 09.08.20

    • Clinical Trials | Drug Development
      FDA Response to COVID-19

      FDA Response to COVID-19

      A Discussion on Protocol Amendments and Clinical Study Reports in Affected Ongoing Trials.
      Jack Modell, M.D., Vice President and Senior Medical Officer, Rho 09.03.20

    • Clinical Trials | Drug Development
      Beyond 2020: The Future of CROs

      Beyond 2020: The Future of CROs

      How will remote site access impact the CRO business?
      Ryan Jones, CEO, Florence Healthcare 08.21.20


    • Biologics, Proteins, Vaccines | Clinical Trials | Drug Development
      Global Biotech: Leading Health Care Innovation and How CROs Are Adapting to Meet Their Needs

      Global Biotech: Leading Health Care Innovation and How CROs Are Adapting to Meet Their Needs

      New models from CROs are enabling further biotech expansion
      Davide Garrisi, Biotech Portfolio Lead, PPD Biotech 08.20.20

    • Clinical Trials | Drug Development
      Pharma’s Imperative: Rethinking the FSP Outsourcing Paradigm

      Pharma’s Imperative: Rethinking the FSP Outsourcing Paradigm

      Evaluating outsourcing strategies amid a complex trial landscape to further enhance clinical operations.
      Michael D. Jones , Vice President of Clinical FSP Client Engagement, IQVIA 08.17.20

    • Biologics, Proteins, Vaccines | cGMP Manufacture | Drug Development
      Tackling Analytical Challenges in Gene Therapy

      Tackling Analytical Challenges in Gene Therapy

      Key considerations on how to navigate the field as a gene therapy developer.
      Khanh Ngo Courtney, Ph.D., Biologics Project Director, Avomeen 07.17.20


    • Drug Development | GMPs/GCPs | Information Technology | QA/QC
      Solving Compliance Challenges and Beyond with Natural Language Processing

      Solving Compliance Challenges and Beyond with Natural Language Processing

      Understanding new data sources and elevating compliance to drive innovation.
      Updesh Dosanjh, Practice Lead, IQVIA Vigilance Platform, IQVIA, Jane Reed, Head of Life Science Strategy, Linguamatics, an IQVIA company 06.16.20

    • Biologics, Proteins, Vaccines | Clinical Trials | Drug Development | Logistics
      The Importance of CAR-T Cell Therapy in Clinical Trials

      The Importance of CAR-T Cell Therapy in Clinical Trials

      The Industry’s Evolving, Maturing Focus
      Panteli Theocharous, Global Vice President, Cell and Gene Therapy Strategy Lead, PPD 05.26.20

    • cGMP Manufacture | Clinical Trials | Drug Development | Information Technology | R&D
      COVID-19’s Long-Term Impact on Drug Development: The New Pragmatism

      COVID-19’s Long-Term Impact on Drug Development: The New Pragmatism

      The rise of new tools and approaches, an increase in regulatory responsibility, and the need for speed.
      Paul Bridges SVP Worldwide Head Regulatory & Access, Parexel and Sheela Hegde, Partner and Managing Director, Health Advances 05.18.20

    Trending
    • Integrated Continuous Manufacturing ICM
    • Humanigen, Emergent Enter Covid-19 Partnership
    • Samsung Bioepis Opens New Headquarters
    • CDMO Northway Biotech Expands In U.S.
    • CONTINUUS Awarded $69.3M DoD Grant
    Breaking News
    • X-Chem Acquires IntelliSyn and AviSyn
    • Aphena’s $21M Cookeville Expansion Nears Completion
    • BioMed X Partners with Jansen Research & Development LLC
    • Care Access Research, AstraZeneca Partner on COVID-19 Antibody Trial
    • 500+ Sites Join Inato’s Industry Marketplace
    View Breaking News >
    CURRENT ISSUE

    November/December 2020

    • Modeling Process Safety Workflows in Pharmaceutical Manufacturing Scale-Up
    • Ensuring Quality During the Transfer and Scale Up of Rx Drugs
    • Inspecting the Unexpected
    • Cold Chain Trends
    • Catering for the Complex
    • Biopharma Contract Manufacturing: Robust Growth Ahead
    • DCAT President Talks COVID-19, Drug Manufacturing and Innovation
    • The Single-Use Mixing Landscape: Evaluating Your Options
    • Self-Medication: Flexibility for Patients and Drug Manufacturers
    • Decentralized Trials Fuel AI Revolution in Clinical Research
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Kerry Launches Web-Based Tool for Plant-Based Formulation Challenges
    Wiley’s Finest Earns Accolades for Taste of Omega-3 Products
    Clinical Evidence Suggests Potential Oral Benefits for Curcumin Extract
    Coatings World

    Latest Breaking News From Coatings World

    Scott McLaughlin to Race in PPG Colors During Rookie INDYCAR Season
    Vink Chemicals Offers parmetol PSG
    Palmer Holland Expands Roles, Positions Of Business Teams
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    BD Names Chairman of BoD
    Interplex Acquires OCP Group
    FDA Clears a Portable Hemodialysis System
    Contract Pharma

    Latest Breaking News From Contract Pharma

    X-Chem Acquires IntelliSyn and AviSyn
    Aphena’s $21M Cookeville Expansion Nears Completion
    BioMed X Partners with Jansen Research & Development LLC
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    The Estée Lauder Companies Announces Game-Changing Sustainability Goals for Travel Retail
    Aura Introduces Customizable Hair Care
    Corpack Creates Custom Packaging for Marlies Möller Hair Care Line
    Happi

    Latest Breaking News From Happi

    Harry’s Launches ‘Headquarters’
    Henkel Recognizes Top Suppliers
    Estée Lauder Travel Retail's Sustainability Goals
    Ink World

    Latest Breaking News From Ink World

    Smurfit Kappa Sets New Sustainability Targets with Better Planet 2050
    Paragon Expands Direct Mail Capabilities with Ricoh Pro VC70000
    Rondo Ganahl Adds Koenig & Bauer Durst Delta SPC 130
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    ACTEGA removes chemicals from laminating adhesives
    Mat Jones joins Grafotronic
    UPM Raflatac unveils new linerless labeling product
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Kimberly-Clark Releases Q4, Full Year Results
    Freudenberg to Establish Apparel Interlining Competence Centers
    Minet Adds Spunlace Line in Romania
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Spinal Elements' Lucent XP-Curved Expandable TLIF Gains FDA Nod
    FDA OKs OrthoSpin's 2nd Gen Robotic, Digital External Fixation System
    Nextremity Solutions Enters Supply Agreement with Fort Wayne Metals
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    North American Semiconductor Equipment Industry Posts December 2020 Billings
    First Solar Signs Definitive Agreement to Sell US Development Platform to Leeward
    PRINTING United Alliance Announces TAGA Presents Virtual Event

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login